About this Research Topic
Since the approval of the first monoclonal antibody therapy over 25 years ago, rituximab, for treating hematological malignancies, the landscape of immunotherapies and cell therapies in cancer has rapidly evolved. Now, the pipeline of immune therapies including CAR-T cells, bispecific antibodies, and checkpoint inhibitors, all feature in a new wave of advanced therapeutic medicinal products. These new treatment modalities offer new and highly effective options; nevertheless, side effects can be frequent or difficult to manage. In addition, with their commercialization, new or unexpected safety events may be reported, thus making ongoing surveillance crucial.
This Research Topic will focus on adverse events and side effects that can arise with new medicines, focusing on but not restricted to immune and cell therapies. Our goal is to gather new evidence related to the diagnosis, management, and epidemiological features of these safety events, to help clinicians of different specialties recognize and treat these conditions.
Researchers are encouraged to submit Original Research articles, Reviews, Mini-reviews, Systematic Reviews, and exceptional Case Reports about the short- and long-term side effects of:
- CAR-T cell treatments
- Immune checkpoint inhibitors
- Bispecific antibodies
- Other advanced therapeutic medicinal products
Salvatore Fiorenza has filed patents on optimizing CAR-T cell cytotoxicity; has received research laboratory grants from Bristol Myers Squibb; and has consulted ad hoc for Prescient Therapeutics.
This Research Topic will focus on adverse events and side effects that can arise with new medicines, focusing on but not restricted to immune and cell therapies. Our goal is to gather new evidence related to the diagnosis, management, and epidemiological features of these safety events, to help clinicians of different specialties recognize and treat these conditions.
Researchers are encouraged to submit Original Research articles, Reviews, Mini-reviews, Systematic Reviews, and exceptional Case Reports about the short- and long-term side effects of:
- CAR-T cell treatments
- Immune checkpoint inhibitors
- Bispecific antibodies
- Other advanced therapeutic medicinal products
Salvatore Fiorenza has filed patents on optimizing CAR-T cell cytotoxicity; has received research laboratory grants from Bristol Myers Squibb; and has consulted ad hoc for Prescient Therapeutics.
Keywords: biologicals, side effects, CAR-T cells, immunotherapy, targeted therapies, real-world data, cancer treatments
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
